Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies. Scheduling and sequencing remain key issues in the design of VDA-chemotherapy combination treatments. This study examined the antitumour activity of ZD6126, a microtubule destabilising VDA, in combination with paclitaxel (PTX), a microtubule-stabilising cytotoxic drug, and the influence of schedule and sequence on the efficacy of the combination. Nude mice bearing MDA-MB-435 xenografts received weekly cycles of ZD6126 (200 mg kg(-1) i.p.) administered at different times before or after PTX (10, 20, and 40 mg kg(-1) i.v.). ZD6126 given 2 or 24 h after PTX showed no significant benefit, a result that was attributed to a protective effect of PTX against ZD6126-induced vascular damage and tumour necrosis, a hallmark of VDA activity. Paclitaxel counteracting activity was reduced by distancing drug administrations, and ZD6126 given 72 h after PTX potentiated the VDA's antitumour activity. Schedules with ZD6126 given before PTX improved therapeutic activity, which was paralleled by a VDA-induced increase in cell proliferation in the viable tumour tissue. Paclitaxel given 72 h after ZD6126 yielded the best response (50% tumours regressing). A single treatment with ZD6126 followed by weekly administration of PTX was sufficient to achieve a similar response (57% remissions). These findings show that schedule, sequence and timing are crucial in determining the antitumour efficacy of PTX in combination with ZD6126. Induction of tumour necrosis and increased proliferation in the remaining viable tumour tissue could be exploited as readouts to optimise schedules and maximise therapeutic efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 2×
“…therapy) or to damage already formed vessels (vascular targeting/disrupting therapy) have been developed and have shown efficacy in preclinical models, and recently, in clinical studies (Taraboletti and Margosio, 2001; Thorpe, 2004; Ferrara and Kerbel, 2005; Tozer et al, 2005; Chaplin et al, 2006).”
BackgroundLineage Infidelity of MDA-MB-435 Cells
Sellappan, S., Grijalva, R., Zhou, X., Yang, W., Eli, M. B., Mills, G. B., & Yu, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3299-2 · Cited by 163 · cited 2×
“The human MDA-MB-435 cancer cell line (Price et al, 1990; Sellappan et al, 2004) was obtained from the NCI-DCTD Tumour Repository, Frederick, MD, USA.”
BackgroundMethod
Cited by
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Combination of nanotechnology with vascular targeting agents for effective cancer therapy
Jahanban‐Esfahlan, R., Seidi, K., Banimohamad‐Shotorbani, B., Jahanban‐Esfahlan, A., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26051 · Cited by 84
“, 2011), several synthetic drugs (Abbasi, Monfaredan, Hamishehkar, Seidi, & Jahanban-Esfahlan, 2014; Martinelli et al., 2007) and some human/plant derived proteins (Bhandarkar & Arbiser, 2007; Collen et al.”
Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation
Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N. (2017) · Tumor Biology · doi:10.1177/1010428317691001 · Cited by 41
Metadata
- Authors
- Martinelli, M., Bonezzi, K., Riccardi, E., Kuhn, E., Frapolli, R., Zucchetti, M., Ryan, A. J., Taraboletti, G., & Giavazzi, R.
- Venue
- British Journal of Cancer
- Published
- 2007-09-11
- Volume
- 97
- Issue
- 7
- Pages
- 888-894
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2000820465
- Cited by
- 53
- References
- 2
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.